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The 2018 Ocular Oncogenesis and Oncology Conference was held through a
partnership of the Association for Research in Vision and Ophthalmology (ARVO) and
the Champalimaud Foundation. Twenty-one experts from international ocular
oncology centers, from the Champalimaud Clinical Centre and the Champalimaud
Foundation Cancer Research Program, and from patient advocacy organizations,
delivered lectures on subjects that ranged from global ocular oncology, to basic
research in mechanisms of ocular malignancy, to clinical research in ocular cancers,
and to anticipated future developments in the area. The scientific program of the
conference covered a broad range of ocular tumors—including uveal melanoma,
retinoblastoma, ocular surface tumors, and adnexal and intraocular lymphomas—and
pathogenesis and management were deliberated in the context of the broader
systemic cancer discipline. In considering the latest basic and clinical research
developments in ocular oncogenesis and oncology, and providing the opportunity for
cross-talk between ocular cancer biologists, systemic cancer biologists, ocular
oncologists, systemic oncologists, patients, and patient advocates, the forum
generated new knowledge and novel insights for the field. This report summarizes
the content of the invited talks at the 2018 ARVO-Champalimaud Foundation Ocular
Oncogenesis and Oncology Conference.
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Introduction
The Ocular Oncogenesis and Oncology Conference
was held on July 18 to 21, 2018 at the Champalimaud
Centre for the Unknown in Lisbon, Portugal, through
a collaborative partnership between the Association
for Research in Vision and Ophthalmology (ARVO)
and the Champalimaud Foundation. The goal of this
unique conference was to consider the latest basic and
clinical research developments in ocular oncogenesis
and oncology in the context of the systemic cancer
field. In applying advances in systemic oncogenesis
and oncology to the ocular field, the scientific
program focused on malignant tumors of the eye,
including uveal melanoma, retinoblastoma, ocular
surface tumors, and adnexal and intraocular lympho-
mas. Topics that were covered included global
perspectives in ocular oncology, research on onco-
genic mechanisms, including genetic, immunologic,
and basic cell and molecular biologic aspects, results
of recent oncologic preclinical studies and clinical
trials in diagnostics and therapies, and anticipated
future progress toward improving outcomes in ocular
cancer.
The conference included 21 invited talks, with
opening and closing keynote lectures given by
international experts in oncogenesis and oncology
from ophthalmic oncology centers around the globe,
from the Champalimaud Foundation, and from
patient advocacy organizations. At the close of the
meeting, participants uniformly agreed that the
intermingling of knowledge, including divergent
points of view, from basic scientists researching in
oncogenesis, ocular oncologists practicing worldwide,
clinicians researching and managing systemic cancer,
and patients and patient advocates, had propelled the
field forward. To share the knowledge that has been
gained through the interactions of these distinct, but
mutually informative, disciplines, this report summa-
rizes the content of the invited talks delivered at the
conference.
Global Perspectives in Ocular
Oncology
Dr. Brenda Gallie described how retinoblastoma
can become a ‘‘zero death’’ cancer. Outcomes for 8000
children newly diagnosed with retinoblastoma each
year depend on where they are born: globally 70% die,
but with resources and knowledge more than 95%
survive.1 The complexity of retinoblastoma con-
founds conventional clinical research. Multidisciplin-
ary care requires hundreds of clinical encounters at
multiple centers with unique medical records, imped-
ing communication, and continuity of care. DEPICT
HEALTH (previously called DePICTRB) is a novel
tool ready to address these needs and support quality
research for retinoblastoma.2 At each encounter
clinical data are entered by caregivers and viewed by
a patient-defined circle of care. The global network of
retinoblastoma experts (1rbw.org) and patients (we-
chope.org) has a long history of effective collabora-
tion, and welcomes DEPICT HEALTH, which can
(1) collect global patient data across The Cloud and
provide patients immediate access to their health
information, and (2) provide real-world data to
generate real-world evidence and support the goal of
zero deaths from retinoblastoma.
Dr. Rubens Belfort discussed the Brazilian model
for addressing gaps in access to ocular oncology. He
presented the challenges of offering ocular oncology
care in Brazil and described new strategies, including
the use of telemedicine and Internet-based teaching to
both patients and general ophthalmologists. Brazil is
a large country with 207 million people, and 70% of
the population does not have medical insurance and
depends on government-funded health care. For the
past 8 years, his team has worked to improve ocular
cancer outcomes by promoting early diagnosis and
efficient care despite substantial financial constraints.
He described the following initiatives: the mobile
phone WhatsApp-based ocular oncology ‘‘second
opinion’’ app, called ‘‘Oncophone’’; YouTube-based
ocular oncology videos for patients and ophthalmol-
ogists (www.cancerocular.com.br); the ocular oncol-
ogy center in the Amazonian region; and some low-
cost strategies for tumor treatment, including primary
endoresection for uveal melanoma3 and laser for
conjunctival tumors.4
The work of Dr. Junyang Zhao in managing
retinoblastoma in China illustrated how care for
ocular tumors may be coordinated across a large
population base. Starting in 2006, he and Dr. Gallie
have collaborated to set up a network for the
management of Chinese children with retinoblastoma.
Today this network covers two-thirds of the country’s
9.6 million–km2 area and includes 29 centers. Dr.
Zhao visits each center every few months, and he has
adopted standard protocols in diagnosis, classifica-
tion, treatment, and follow-up for every patient. He
treats more than 300 new cases of retinoblastoma
every year. He has documented the following
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outcomes in his clinical practice: increased 5-year
follow-up rate from 48% of cases of retinoblastoma
(2006–2009) to more than 95% cases (2013–2016);
decreased mortality from 21% to 5%; and increased
eye-salvage rate from 20% to over 80% when
vitrectomy and tumor resection are performed.5,6
The opening keynote lecture, entitled ‘‘Patient of
the future–making use of a valuable resource,’’ was
delivered by Dr. Bettina Ryll. The ultimate beneficia-
ries of healthcare systems are patients. In times when
demands for a more patient-centered care are
accompanied by increasing constraints on resources,
patients can provide unique experiential insights into
diverse conditions, the desired and undesired effects
of therapy, and the effectiveness of healthcare
delivery. In that regard, patients probably represent
the largest underused resource in our healthcare
systems. However, leveraging this resource for im-
proved healthcare decision-making will depend on
accurately capturing and representing patient prefer-
ences in all their diversity and granularity, both
between and within conditions. In a collaboration
with the European Medicines Agency, the Melanoma
Patient Network Europe (MPNE) has piloted meth-
odology to capture risk–benefit preferences in differ-
ent groups of its audience, and believes this is a
possible way forward to treat and to decide on behalf
of individuals rather than hypothetical averages.7
Basic Science Research on Ocular
Oncogenesis
Taking a systemic perspective, Dr. Eduardo
Moreno spoke on cell competition and cancer. Direct
comparison of cell fitness in Drosophila species is used
to detect and eliminate many types of viable, but
impaired, cells to delay ageing and prevent develop-
mental malformations. In humans, opportunities for
fitness-based cell selection have also been described
during development and cancer, but they normally
rely on indirect competition for survival factors or
nutrients, and whether a system dedicated to direct
comparison of cell fitness is conserved in humans is
unknown. His group has studied human Flower
isoforms and found that expressing ‘‘Win’’ isoforms
2 and 4 gives cells a competitive advantage over those
expressing ‘‘Lose’’ isoforms 1 and 3.8 Lose-expressing
cells are not culled if neighboring cells have similar
levels of Lose, and therefore act as canonical fitness
fingerprints. They have also found that human
tumors benefit from fitness-based cell selection to
gain competitive growth. These results illustrate how
ancient mechanisms of cell recognition and selection
are active in humans and impact oncogenic
growth.9,10
Dr. Steffen Heegaard talked about basic mecha-
nisms of conjunctival and orbital lymphoma. Lym-
phoma is the sixth most common type of cancer, with
20 cases per 100,000 persons per year in the Western
World. Approximately 90% of lymphomas are of B-
cell origin; 1% to 2% of these occur in the ocular
region, and lymphoma is the most common malignant
orbital tumor. Risk factors for developing lymphoma
are inflammatory diseases, such Sjgren’s syndrome,
systemic lupus erythematosus, rheumatoid arthritis,
celiac disease, and autoimmune thyroiditis. Infectious
pathogens known to cause lymphoma include the
bacterium, Helicobacter pylori, and the viruses,
hepatitis C virus, human herpes virus-8, Epstein-Barr
virus, and human immunodeficiency virus. Little is
known about why tumor lymphocytes settle down in
a specific tissue. However, this process of ‘‘homing’’ is
regulated by adhesion molecules and their interplay
with chemokines in lymphoid tissue.11 Extranodal
marginal zone B-cell lymphomas are presumed to
develop due to infection and inflammation causing
cell damage, leading to an increase in reactive oxygen
species, and if chromosomal instability develops,
malignant transformation may occur.12 Several chro-
mosomal abnormalities associated with extranodal
marginal zone B-cell lymphomas include trisomy 3,
trisomy 18, and some chromosomal translocations
(i.e., t[11;18] ! API2-MALT1, t[14;18] ! IGH-
MALT1, t[1;14]! Bcl10-IGH, and t[3;14]! FoxP1-
IGH). Most of these chromosomal changes lead to an
abnormal activation of the transcription factor,
nuclear factor kappa-light-chain-enhancer of activat-
ed B cells (NF-jB).
Dr. Sarah Coupland gave an update on the basics
of intraocular lymphoma. Primary vitreoretinal lym-
phoma is the most common intraocular lymphoma.13
It is a high-grade typically B-cell malignancy, arising
in the retina, and is often associated with central
nervous system disease, and thereby a poor prognosis.
This form of lymphoma must be distinguished from
low-grade B-cell choroidal lymphoma, which does not
disseminate to the brain and has a good prognosis, as
well as from secondary ocular manifestations of
systemic lymphomas. Vitreoretinal lymphoma often
‘‘masquerades’’ as another intraocular disease and
therefore may be associated with diagnostic delay.
Pathologic work-up includes cytomorphology and
immunoprofiling with adjunctive tests, such as
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cytokine analysis, polymerase chain reaction (PCR)
for immunoglobulin gene rearrangements, MYD88
mutational testing, and recently, bespoke next-gener-
ation sequencing panels.14–16 Vitreoretinal lympho-
mas arise from activated postgerminal center cells,
explaining their aggressive clinical course.13
Dr. Bruce Ksander discussed the pathogenesis of
conjunctival and uveal melanomas. Skin and choroi-
dal melanomas are clinically and genetically distinct
tumors even though they both arise from the
malignant transformation of normal melanocytes.
The reason for this must reside, in part, in the
differences between the function of melanocytes in
skin and eye. The function of melanocytes in the skin
has been studied extensively, while very little is known
about the function of choroidal and conjunctival
melanocytes. Skin and conjunctival melanomas share
mutations that activate the mitogen-activated protein
kinase (MAPK) pathway (i.e., BRAF, NRAS, NF1
genes), indicating skin and conjunctival melanocytes
acquire similar ultraviolet radiation–induced muta-
tions. Improving the current treatment regimens for
patients with conjunctival melanoma will require
further studies on the mechanisms of tumor growth
and dissemination using new animal models.17,18 By
contrast, uveal melanomas have mutations in genes
encoding G-coupled protein receptors (i.e., GNA11,
GNAQ) or mutations in genes that signal through Ga
subunits (i.e., CYSLTR2, PLCB4). Other gene muta-
tions (i.e., BAP1, SF3B1, EF1AX) are believed to have
a cooperative role in determining the aggressiveness of
tumor expansion.19 A recent important new mouse
uveal melanoma transgenic model confirms the con-
tributions of GNA11 and BAP1 gene mutations in
tumor growth, but also indicates our understanding of
the genetic pathogenesis of uveal melanoma is not fully
complete.20 Development of new successful therapies
for patients with uveal melanoma will depend upon
understanding the function of normal ocular melano-
cytes and animal models that trigger their malignant
transformation.
The immunology of ocular melanoma was ad-
dressed by Dr. Martine Jager. Uveal melanoma is the
most common primary malignancy in the adult eye.
Loss of chromosome 3 and gain of 8q, and somatic
mutations in the BAP1 gene, located on chromosome
3, are associated with an increased risk of developing
metastases. Loss of BAP1 expression is associated
with increased inflammation.21 As immunotherapy is
currently being developed for many malignancies, one
might expect that inflamed uveal melanoma would be
a readily druggable target. However, most studies on
the clinical use of immune checkpoint inhibitors—
including inhibitors of cytotoxic T cell lymphocyte-
associated antigen 4 (CTLA-4), programmed cell
death protein 1 (PD-1), and programmed death-
ligand 1 (PD-L1)—have not shown success with
regard to the treatment of uveal melanoma metasta-
ses. These drugs may be more effective for conjunc-
tival melanoma, a malignancy that is more similar to
cutaneous melanoma.22
Dr. Hans Grossniklaus reflected on the Zimmer-
man effect as he described the mechanisms of
metastatic uveal melanoma. In the 1970s, Zimmer-
man and colleagues noted that the peak in mortality
for metastatic uveal melanoma was at approximately
2 to 3 years after enucleation of the eye with the
melanoma; this has become known as the ‘‘Zimmer-
man effect.’’ Zimmerman hypothesized that the act of
enucleation spread tumor cells.23 This, in part, led to
the establishment of the Collaborative Ocular Mela-
noma Study (COMS). The COMS confirmed the
Zimmerman effect, but disproved the Zimmerman
hypothesis.24 Dr. Grossniklaus’ laboratory group and
others have since found explanations for the Zimmer-
man effect. These include that there are random
mutations in uveal melanoma, resulting in larger
tumors giving rise to more metastases than smaller
tumors, and that specific mutations are associated
with peaks in uveal melanoma mortality at approx-
imately 3 and 5 to 8 years after treatment.25
Additionally, host immune and nonimmune factors
account for emergence and growth of dormant uveal
melanoma micrometastases in the liver over time.26
Clinical Research in Ocular Oncology
Using breast cancer as an example, Dr. Fatima
Cardoso stressed the critical importance of working
from bench to bedside in evaluating genomic and
biomarker tests for clinical application.27 At the
bench, all potential testing requires technical valida-
tion. This necessitates confirmation of sensitivity,
specificity, and reproducibility. Subsequently, the
proposed test must be clinically validated by identi-
fying meticulously phenotyped subsets of patients
with cancer, who manifest significant differences in
risks for relapse, and/or for response to precise
therapies. She described the development of Mam-
maPrint, a 70-gene genomic signature that is able to
identify patients who have an excellent prognosis
when treated with adjuvant endocrine therapy alone
and in whom adjuvant chemotherapy may be safely
omitted.28
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Dr. Dan Gombos summarized the treatment of
primary and metastatic uveal melanoma. In 2018, the
diagnosis and management of uveal melanoma stands at
a significant crossroad, with outstanding diagnostic
accuracy and prognostication, yet limited improvements
in patient survival.29 Clinical features, combined with
multimodal imaging, generally lead to an accurate
diagnosis. Size, location, and histopathology facilitate
in stratifying metastatic risk. Combined with DNA or
RNA molecular assessment, those at highest risk for
distant metastasis are easily identified.30 Local treatment
options, including brachytherapy or charged particle
radiation, have improved and now allow globe preser-
vation in all but the most advanced cases. Experimental
approaches using laser-stimulated viral plasmids are
under investigation. Following ocular therapy, a per-
sonalized surveillance regimen targets those at highest
risk of metastasis with greatest frequency. Current
survival rates are not improving, however, although new
immune and targeted therapies may be sound platforms
for adjuvant therapies that target metastasis. Identifying
high-risk patients and enrolling them in well-designed
prospective clinical trials is the next critical step toward
curing this malignancy.31
Dr. Swathi Kaliki reported the latest in the
management of ocular surface squamous neoplasia.
The gold standard method of diagnosis of this
squamous neoplasia is histopathology, and standard
management is with wide excisional biopsy, respecting
3- to 4-mm tumor-free margins, followed by double
freeze-thaw cryotherapy to the surgical margins and
ocular surface reconstruction. However, in the recent
times, the neoplasia may be diagnosed using the
noninvasive technique of high-resolution optical
coherence tomography (OCT), and various nonsurgi-
cal techniques have emerged for optimal manage-
ment, including topical mitomycin C (MMC), 5-
fluorouracil (5-FU), and interferon-alpha 2b (IFN-
a2b).32 The tumor regression rates of ocular surface
squamous neoplasia with MMC, 5-FU, and IFN-a2b
are comparable, while the side effects are minimal
with IFN-a2b. In cases with giant neoplasia (i.e., .6
clock-hours of limbal involvement) not responding to
medical treatment, surgical excision may lead to
limbal stem cell deficiency in more than 50% of cases.
Prophylactic concomitant simple limbal stem cell
transplantation after surgical excision of giant ocular
surface squamous neoplasia can prevent or minimize
limbal stem cell deficiency.33
Old paradigms and new challenges of cancer and
organ preservation were considered by Dr. Carlos
Carvalho. In the last few decades, most patients with
uveal melanoma and retinoblastoma have been
successfully treated without surgical enucleation.
The possibility of organ and function preservation
in the tumors of the eye also applies to other solid
tumor types (i.e., head and neck, esophagus, cervix,
prostate, rectum, and anal canal) where radiotherapy
and/or chemotherapy may be able to induce a
complete ‘‘remission’’ and eventually avoid a surgical
amputation.34 To achieve organ preservation, the
treatment must induce not only a transient remission,
but a sustained complete response. This particular
biology may depend not only on the tumor cell
sensitivity to the treatment, but also on the interac-
tions between the tumor and its microenvironment
and particularly on an ‘‘adjuvant’’ effect that is
mediated by the immune system. The characterization
of the tumor–host individual immune profile may be
the key to better understanding the biology of a
complete response, and to open more doors, not only
to better organ and function preservation, but also to
new treatment strategies.35,36
Dr. Jasmine Francis described current treatment of
retinoblastoma, focusing on ophthalmic artery che-
motherapy and intravitreous chemotherapy. The
main present-day treatment for retinoblastoma at
her institution involves ophthalmic artery chemosur-
gery and intravitreous chemotherapy. Recent studies
have covered various pertinent topics. Eyes that
successfully complete ophthalmic artery chemosur-
gery may have recurrent disease, but the overall
ocular survival rate is 96%; factors associated with
reduced recurrence include an interval shorter than 4
weeks between infusions and over 50% of infusions
delivered via the ophthalmic artery (in contrast to
indirect routes).37 Ophthalmic artery chemosurgery
has a major impact on the outcome of patients with
bilateral retinoblastoma, particularly on historically
high ocular survival rates.38 Combining ophthalmic
artery chemosurgery with intravitreous chemotherapy
results in a faster time to regression, less future
recurrence, and more eyes saved.39 The use of
intravitreous chemotherapy expands beyond vitreous
disease to the treatment of retinal, subretinal, and
anterior chamber retinoblastoma with excellent ocu-
lar survival, and the majority of eyes retaining or
gaining electroretinogram responses.40
Dr. Jacob Pe’er reviewed the current management
of vitreoretinal lymphoma. The suspicion of vitreo-
retinal lymphoma is raised when ocular findings
include vitreous cells, mainly in clumps, which is the
most common finding, yellow-white retinal infiltrates,
and subretinal or subretinal pigment epithelial infil-
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trates by OCT. The diagnosis is usually made by
vitreous biopsy analyzed by cytology, including
immunocytopathology, which considered to be a gold
standard, by PCR for molecular analysis for the IGH
gene rearrangement and mutated MYD88, and by
cytokine analysis mainly by measuring the interleukin
(IL)-10:IL-6 ratio.41 Cytokine levels in the anterior
chamber and rarely chorioretinal biopsy also may be
used. Results for a group of 150 patients at his clinical
service indicate that in the associated laboratory, the
IL-10:IL-6 ratio is more sensitive than cytology or
PCR in the diagnosis of vitreoretinal lymphoma,
leading to his recommendation that analysis of
cytokine levels is a robust diagnostic tool in cases of
suspected vitreoretinal lymphoma. Vitreoretinal lym-
phoma may be treated by radiation therapy, chemo-
therapy using systemic, intrathecal, and intravitreal
routes, and biological therapy using rituximab. For
over 20 years, his clinic has used only intravitreal
injection of methotrexate—administering (400 lg) per
injection and giving 25 injections over 1 year, as one
injection twice per week for 1 month, one injection
per week for 2 months, and one injection per month
for 9 months42—to treat 122 eyes of 74 patients,
including 48 binocular cases. All patients responded
fully after two to 16 injections. Tumor recurred in
only two eyes, and these were treated successfully with
a full second course of methotrexate. Side effects were
mostly superficial and temporary. The group has
concluded that intravitreal chemotherapy with meth-
otrexate is a highly effective treatment for vitreoret-
inal lymphoma.
Looking to the Future Management of
Ocular Cancer
Dr. Markus Maeurer presented immune surgery as
a possible approach for patients with uveal melano-
ma. The advent of immune therapies has extended our
view of cancer therapy—from focusing on tumor cell
biology to the wider angle of a complex tumor
ecosystem with diverse immune cell subsets interact-
ing with evolving tumor cell populations—at different
anatomic sites and at different timepoints during the
treatment process. A number of highly effective
cellular therapies have been developed, targeting
overexpressed tumor-associated antigens and com-
mon mutations as well as the patients’ personal
‘mutanome’, associated with the antigen processing
and presentation machinery.43,44 In contrast to the
situation of cutaneous melanoma, major histocom-
patibility complex (MHC) class I loss in primary
uveal melanoma appears to be associated with
improved survival. Detailed mapping of the determi-
nants of immune failure and immune fitness in the
tumor ecosystem will be key to developing targeted
approaches that provide biologically and clinically
meaningful, ‘tailored’ cellular products for therapy,
dependent on MHC expression in primary or
metastatic uveal melanoma lesions.
Ocular complications of new oncologic treatments
were discussed by Dr. Arun Singh. The rapid
advancements in the field of oncology have resulted
in the transition from cytotoxic chemotherapeutic
agents to molecularly targeted therapies. The complex-
ity of cellular pathways creates challenges for designing
therapeutic agents that do not overlap with the
physiologic activities of the normal human tissues.
Distinct patterns of adverse effects related to the
molecularly targeted therapies have emerged with their
increased clinical usage. Molecularly targeted agents act
through a variety of mechanisms, which result in side
effects related to a specific agent. Most ocular tissues
are susceptible, with effects on periocular skin, the
ocular surface, neurosensory retina, and central visual
pathways.45 The majority of ocular toxicities reported
are mild and nonspecific (i.e., conjunctivitis, epiphora,
and visual disturbances); severe blinding complications
are rare.46,47 Given the complexity of the clinical setting
in which targeted therapies are used, a multidisciplinary
approach for management is required.
Dr. Jose Pulido spoke on the hamartia of
checkpoint inhibitors and the emergence of viroim-
munotherapy for uveal melanomas. Recent use of
immunotherapy with checkpoint inhibitors has made
a major impact on the progression-free and overall
survival in patients with many solid cancers, including
cutaneous melanoma.48 The efficacy is closely related
to the number of mutations per megabase, with the
higher number having the greater efficacy.49 Unfor-
tunately, uveal melanomas have the lowest number of
mutations per megabase of solid cancers studied, and
consequently the worst response to checkpoint
inhibitors of any solid cancer. There are many
differences between cancer cells and normal cells.
The most well-known difference is the increase in
glycolysis in cancer cells, causing the Warberg effect
and the ability of positron emission tomographic
scans to visualize tumors.50 Another difference is that
some cancer cells are more susceptible to viral
infection because they are replicating and because
they do not respond to interferons. Oncolytic
virotherapy involves preferentially infecting growing
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cancer cells with virus.51 However, a challenge in this
therapy is that all cancer cells must be infected.
Viroimmunotherapy uses viruses to trigger an im-
mune response.52 It involves infecting a cancer with
virus, and with epitope spread, to generate an immune
response directed against virus-infected cancer cells
that subsequently targets all cancer cells. Dr. Pulido’s
team showed vesicular stomatitis virus (VSV) with a
prostate cancer DNA library was active against
prostate cancer in a mouse model, but had no effect
in a mouse melanoma model; conversely, VSV with a
melanoma DNA library had promoted survival of
mice with melanoma, but not mice with prostate
cancer.53 They also showed that three tumor-ex-
pressed antigens, not an entire DNA library, was
necessary for therapeutic effect.54 Present work aims
at a clinical trial of VSV expressing an interferon to
augment the difference between cancer and normal
cells, plus a tumor antigen, for metastatic melanoma.
Dr. Laurence Desjardins talked about the future in
the management of ocular tumors, drawing on her
experiences at the French Institut Curie. Here, the
ocular oncology service has been taking a conservative
approach to the management of uveal melanoma since
the early 1980s. Between 300 and 350 new patients are
evaluated each year, and management involves proton
beam therapy, iodine plaque brachytherapy, enucle-
ation for large tumors, and fine needle biopsy for
prognostication; each year 60 to 80 patients present
with metastatic disease. A prospective database with
clinical information from more than 8000 patients, a
collection of primary and liver metastasis samples, and
a serologic collection is housed here. The service has
been responsible for the French national database since
2008, and it coordinates the French national network
for uveal melanoma care (MELACHONAT).55 The
prognosis of patients with metastatic disease is still
poor despite efforts to test new drugs for this disease.
Two years ago, Institut Curie and three other centers
(i.e., Leiden University, University of Liverpool, and
Jagiellonian University), plus two biomedical compa-
nies and the patient association, MPNE, came together
as the UMCURE 2020 Project, to increase research on
uveal melanoma. The Champalimaud Foundation and
Seeding Science also participate in this project. The
consortium’s goals are to develop a European biobank,
preclinical evaluation of biology-driven therapeutic
approaches, next generation preclinical models of
uveal melanoma, characterization of metastatic dis-
ease, identification of novel targets, and clinical trials.
Dr. Richard Carvajal delivered the closing keynote
lecture, entitled ‘‘A new optimism: uveal melanoma in
the era of precision oncology and immuno-oncology.’’
The field of oncology has borne witness to remarkable
progress over the past 15 years in the realms of both
precision medicine and immuno-oncology. The suc-
cessful application of both precision oncology and
immuno-oncology for the treatment of cutaneous
melanoma has resulted our ability to achieve pro-
longed disease control and cures in over 30% of
individuals with metastatic disease. While similar
progress has not yet been achieved in the uveal
melanoma field, the successes achieved in cutaneous
melanoma provide cause for renewed optimism.
While the clinical results of agents targeting activated
signaling pathways downstream of GNAQ, GNA11,
PLCB4, and CYSLTR2 for the treatment of ad-
vanced uveal melanoma have been disappointing to
date,56,57 novel therapeutic strategies addressing
epigenetic aberrations in uveal melanoma have
demonstrated promise preclinically, and now are
being pursued in early phase clinical trials of
bromodomain inhibitors and other epigenetic modi-
fying agents.58,59 In parallel, although to date clinical
trials evaluating the efficacy of immunologic check-
point blockade in this disease have not demonstrated
significant activity, other immunologic treatment
strategies, including adoptive T cell therapy and T
cell redirection, have shown promising early clinical
results, with IMCgp100, a T cell redirection therapy,
now in registration intent clinical trials (Carvajal R, et
al. IOVS 2018;59:ARVO E-Abstract 3622).36 Thus,
our rapidly developing understanding of the underly-
ing biology and immunobiology of uveal melanoma is
leading to a new generation of novel therapies, which
hold great promise in providing meaningful improve-
ment in the lives of our patients with advanced
disease.
Conclusions
The 2018 ARVO-Champalimaud Foundation
Ocular Oncogenesis and Oncology Conference was
the first-of-its-kind, bringing together multiple pro-
fessional and patient groups with a common interest
in improving outcomes for patients with ocular
tumors. Interactions between the different groups
resulted in valuable exchange of concepts across
knowledge bases. As one example, ocular oncologists
learned from systemic oncologists that receptor
status of a cancer may change following metastasis,
introducing the concept of restaging when approach-
ing a metastatic ocular disease. As another example,
ocular and systemic oncologists acknowledged they
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would be a team working toward treating uveal
melanoma with tumor-infiltrating lymphocytes
sourced from metastatic lesions. Separately, the
concept of the mutanome brought basic scientists
and clinicians together in thinking about personal-
ized treatment regimens for individual patients with
ocular cancers. There was also recognition that
oncogenic pathways overlap between uveal and
cutaneous melanomas, which should provide for
future cross-pollination in the development of
biological inhibitor therapies. Importantly, ocular
and systemic oncologists learned that patients and
patient advocates differ substantially in their respec-
tive desires for knowledge of pathology and treat-
ment, which has important implications for trial
design, as well as clinical management. These
interactions at the 2018 ARVO-Champalimaud
Foundation Ocular Oncogenesis and Oncology
Conference highlighted the value of cross-disciplin-
ary meetings involving basic, translational, and
clinical researchers, working within and outside the
eye field, as well as patient groups.
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